JP2023545084A - Ｏｘ４０関連疾患を治療するための方法 - Google Patents

Ｏｘ４０関連疾患を治療するための方法 Download PDF

Info

Publication number
JP2023545084A
JP2023545084A JP2023521639A JP2023521639A JP2023545084A JP 2023545084 A JP2023545084 A JP 2023545084A JP 2023521639 A JP2023521639 A JP 2023521639A JP 2023521639 A JP2023521639 A JP 2023521639A JP 2023545084 A JP2023545084 A JP 2023545084A
Authority
JP
Japan
Prior art keywords
weeks
antibody
disease
treatment
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545084A5 (https=
Inventor
光男 佐藤
吉範 永田
顕司 大瀧
信行 今井
宗健 島辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of JP2023545084A publication Critical patent/JP2023545084A/ja
Publication of JP2023545084A5 publication Critical patent/JP2023545084A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023521639A 2020-10-09 2021-10-08 Ｏｘ４０関連疾患を治療するための方法 Pending JP2023545084A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063089809P 2020-10-09 2020-10-09
US63/089,809 2020-10-09
US202063116365P 2020-11-20 2020-11-20
US63/116,365 2020-11-20
US202163233592P 2021-08-16 2021-08-16
US63/233,592 2021-08-16
PCT/JP2021/037481 WO2022075476A1 (en) 2020-10-09 2021-10-08 Method for treating ox40 related disease

Publications (2)

Publication Number Publication Date
JP2023545084A true JP2023545084A (ja) 2023-10-26
JP2023545084A5 JP2023545084A5 (https=) 2024-10-15

Family

ID=81126528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521639A Pending JP2023545084A (ja) 2020-10-09 2021-10-08 Ｏｘ４０関連疾患を治療するための方法

Country Status (11)

Country Link
US (1) US20230383001A1 (https=)
EP (1) EP4225371A4 (https=)
JP (1) JP2023545084A (https=)
KR (1) KR20230084166A (https=)
CN (1) CN116437955A (https=)
AU (1) AU2021358274A1 (https=)
CA (1) CA3198414A1 (https=)
IL (1) IL301935A (https=)
MX (1) MX2023004113A (https=)
TW (1) TW202222343A (https=)
WO (1) WO2022075476A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025244002A1 (ja) * 2024-05-21 2025-11-27 国立大学法人京都大学 ベンダムスチンによるｔ細胞の減少を抑制するために使用されるｔ細胞減少抑制剤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326123A (en) * 2023-07-25 2026-03-01 Inmagene Pte Ltd Treatment methods for alopecia areata and atopic dermatitis
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018057849A1 (en) * 2016-09-23 2018-03-29 Genentech, Inc. Uses of il-13 antagonists for treating atopic dermatitis
WO2019229155A1 (en) * 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018057849A1 (en) * 2016-09-23 2018-03-29 Genentech, Inc. Uses of il-13 antagonists for treating atopic dermatitis
WO2019229155A1 (en) * 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIDEMI NAKAGAWA ET AL.: "Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-O", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 99, no. 2, JPN6025039096, August 2020 (2020-08-01), pages 82 - 89, ISSN: 0005697499 *
K.A. PAPP ET AL.: "Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to mode", JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, vol. 31, no. 8, JPN6025039097, 2017, pages 1324 - 1332, ISSN: 0005697500 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025244002A1 (ja) * 2024-05-21 2025-11-27 国立大学法人京都大学 ベンダムスチンによるｔ細胞の減少を抑制するために使用されるｔ細胞減少抑制剤

Also Published As

Publication number Publication date
AU2021358274A9 (en) 2024-05-30
TW202222343A (zh) 2022-06-16
IL301935A (en) 2023-06-01
EP4225371A1 (en) 2023-08-16
AU2021358274A1 (en) 2023-05-25
KR20230084166A (ko) 2023-06-12
CN116437955A (zh) 2023-07-14
WO2022075476A1 (en) 2022-04-14
EP4225371A4 (en) 2024-11-20
MX2023004113A (es) 2023-06-29
CA3198414A1 (en) 2022-04-14
US20230383001A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
TWI852712B (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
JP2022033891A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
JP2023545084A (ja) Ｏｘ４０関連疾患を治療するための方法
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
JP2022028788A (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
US20210214453A1 (en) Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseases
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
JP2009530269A (ja) アレルギー疾患及び慢性炎症性疾患の治療の為の薬学的組成物及びアレルギー疾患及び慢性炎症性疾患の治療方法
WO2025214333A1 (zh) 抗tslp抗体治疗与tslp相关的炎症疾病的方法
KR20250135238A (ko) 면역 매개 괴사성 근병증의 치료 및 예방을 위한 항-cd19 결합제
WO2026078117A1 (en) Anti-il-5 antibody in the treatment of chronic rhinosinusitis with nasal polyps
TW202041536A (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
JP2026503045A (ja) Ｔｓｌｐ抗体を使用して喘息を治療するための方法
US20190247503A1 (en) Methods for treating relapsing forms of multiple sclerosis
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
CN118139885A (zh) 通过施用il-4r拮抗剂以治疗慢性自发性荨麻疹的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260128

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260414